VJOncology Podcast

Hosted by VJOncology

Technology

Website RSS feed

Episodes

229

Latest episode

Aug 2026

Language

EN-GB

About the show

The Video Journal of Oncology (VJOncology) podcast covers the latest oncology news from international experts across a view variety of solid tumors. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjoncology.com

Listen to episodes

60 recent

August 14, 2026Episode 23918 min

Immunotherapy updates in head and neck cancer from ASCO 2026

On this week’s episode of VJOncology podcasts, we bring you head and neck cancer highlights in immuno-oncology from the 2026 ASCO Annual Conference. Join Barbara Burtness from the Yale School of Medicine, Hannah Kenny from Thomas Jefferson University Hospital, Ari Rosenberg from the University of Chicago, Nabil Saba from Emory University, and Kedar Kirtane from Moffitt Cancer Center as they discuss highlights from the meeting. They explore new data from key trials including OrigAMI-4, EV-202 and KEYNOTE-412, as well as emerging cellular therapies and checkpoint inhibitors.

August 7, 2026Episode 23816 min

Updates in skin cancer from ASCO 2026

In this week’s VJOncology podcast, we explore the latest advances in skin cancer from ASCO 2025, with a focus on melanoma and emerging cellular therapies. Join Alexandra Haugh of Massachusetts General Hospital Cancer Center, Boston, MA, Kalijn Bol of Radboud University Medical Center, Nijmegen, Netherlands, Allison Betof Warner of Stanford University, Stanford, CA, Omid Hamid of The Angeles Clinic and Research Institute, Los Angeles, CA, and Peter Forsyth of Moffitt Cancer Center, Tampa, FL, as they discuss real-world outcomes with lifileucel, treatment sequencing in BRAF-mutated melanoma, emerging cellular therapies and vaccines, and preclinical approaches to CAR T-cell therapy for leptomeningeal disease.

July 31, 2026Episode 23719 min

iwCAR-T 2026: advances in TIL therapy for solid tumors

Welcome to another episode of VJOncology Podcast, featuring a roundtable discussion from iwCAR-T 2026, which took place in Tampa, FL. This week, our experts explore advances in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Join Benjamin Creelan from Moffitt Cancer Center, Rodabe Amaria from the University of Texas MD Anderson Cancer Center, Daniel Olson from the University of Chicago, and Lilit Karapetyan from Moffitt Cancer Center as they discuss sequencing, duration issues and armoring approaches for TIL therapy in melanoma and other solid tumors.

July 23, 2026Episode 23617 min

Beyond the algorithm: trust, evidence and equity in AI-enabled cancer care

In this week’s VJOncology podcast, we explore the latest developments in artificial intelligence (AI) in oncology and their potential to transform cancer care. Join Eleonora Teplinsky, Valley Health System, Paramus, NJ, Gil Shamai, Technion–Israel Institute of Technology, Haifa, Israel, Matthew Kurian, St. Elizabeth Healthcare, Edgewood, KY, Jai Patel, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, and Marie Hanaoka, Institute of Science Tokyo, Japan, as they discuss AI-driven patient education, biomarker prediction, clinical decision-making, trial matching, and surgical training, alongside the opportunities and challenges of integrating artificial intelligence into oncology practice.

July 17, 2026Episode 23516 min

GU cancer highlights from ASCO 2026

In this week’s VJOncology podcast, we present highlights in genitourinary cancer from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Join Andrew Armstrong of Duke University Medical Center, Srikala Sridhar of the Princess Margaret Cancer Centre, Tian Zhang of UT Southwestern Medical Center, and Lucia Nappi of the University of British Columbia as they discuss key data and clinical perspectives across prostate, bladder, kidney and testicular cancer, including the PROTEUS, CHAMP, TALAPRO-3, A-DREAM and SWOG S1823 trials, as well as the role of enfortumab vedotin and pembrolizumab in bladder cancer.

July 10, 2026Episode 23418 min

Top updates from the ESMO Gastrointestinal Cancers Congress 2026

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 ESMO Gastrointestinal Cancers Congress in Munich, Germany, where we explored the latest advances across gastrointestinal malignancies. Join Teresa Macarulla, Vall d’Hebron University Hospital, Barcelona, Spain, Giulia Martini, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, Lorenza Rimassa, Hunimed University, Milan, Italy, Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan, and Silvio Ken Garattini, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, as they discuss emerging KRAS G12D-targeted therapies in pancreatic cancer, ctDNA-guided treatment strategies in metastatic colorectal cancer, novel targeted approaches for biliary tract cancer, HER2-directed therapies in gastroesophageal cancer, and evolving treatment paradigms in hepatocellular carcinoma and gastric cancer.

June 26, 2026Episode 23316 min

Highlights in lung cancer from ASCO 2026: LIBRETTO-432, CROWN, and more

This week, VJOncology brings you lung cancer highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Join Alessandro di Federico from the Memorial Sloan Kettering Cancer Center, Erika Ruiz-Garcia of the Instituto Nacional de Cancerologia, Nandini Menon of the Tate Memorial Centre and Bjorn Henning Gronberg of the Norwegian University of Science and Technology as they discuss key trials and data in lung cancer from the meeting. They explore results from the LIBRETTO-432, TRITON and FLAME trials, as well as 7-year follow up data from the CROWN trial. In addition, they discuss two trials of KRAS G12C inhibitors, a study examining low-dose pembrolizumab and a trial of thoracic radiotherapy.

June 19, 2026Episode 23217 min

Breast cancer highlights from ASCO 2026

For this week’s VJOncology podcast, we bring you highlights in breast cancer from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Join Oleg Gluz of Evang. Krakenhaus “Bethesda” Klinik, Jana de Boniface of the Karolinska Institutet, Peter Schmid of Queen Mary University of London and Erika Hamilton of the Sarah Cannon Research Institute as they discuss key trials and what this means for clinical practice. They explore pooled analysis from the ADAPT and PlanB trials, results from the SENOMAC trial of axillary lymph node dissection omission, menopausal status data from the lidERA trial, final analysis from KEYNOTE-522 and subgroup analyses from HER2CLIMB-05.

June 12, 2026Episode 23016 min

Gastrointestinal cancer updates at ASCO 2026: RASolute 302, EMERALD-3, and more

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL, where we explored the latest advances in gastrointestinal (GI) cancers. Join Ghassan Abou-Alfa and Yelena Janjigian of Memorial Sloan Kettering Cancer Center, Scott Kopetz of The University of Texas MD Anderson Cancer Center, and Choong-Kun Lee of Yonsei University as they discuss emerging treatment strategies in GI cancers, including findings from the EMERALD-3, RASolute 302, DESTINY-Gastric03, BREAKWATER, and HERBOT trials, alongside the growing role of targeted therapies, HER2-directed approaches, and biomarker testing in gastrointestinal oncology.

June 8, 2026Episode 22918 min

Highlights from ASCO 2026

In this episode of VJOncology podcasts, we present highlights from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Five leading experts share key data and insights spanning prostate cancer, sarcoma, lung cancer, colorectal cancer, and breast cancer. Dr Mary-Ellen Taplin from Dana-Farber Cancer Institute presents final analysis data from the PROTEUS trial, demonstrating that perioperative apalutamide plus androgen deprivation therapy (ADT) sets a new standard of care in high-risk localized prostate cancer. Dr Maggie Zhou from Stanford University highlights practice-changing findings in sarcoma, including the SARC041 trial of abemaciclib in dedifferentiated liposarcoma. Dr Abdul Rafeh Naqash from the University of Oklahoma Health Sciences Center reviews key lung cancer advances, including results from the DeLLphi-304, LIBRETTO-432, and ALCHEMIST trials. Dr Scott Kopetz from MD Anderson Cancer Center presents progression-free and overall survival data from BREAKWATER Cohort 3, supporting encorafenib plus cetuximab combined with FOLFIRI as a new standard of care in BRAF V600E-mutant metastatic colorectal cancer. Finally, Dr Kevin Kalinsky from Emory University discusses PFS2 data from ASCENT-04, reinforcing sacituzumab govitecan plus pembrolizumab as a standard of care in treatment-naive PD-L1-positive metastatic triple-negative breast cancer. This episode offers essential insights into practice-changing data across five major tumor types from one of the most important oncology meetings of the year.